Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial -

Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial
Information type: Randomised controlled trials
Source: The Lancet Neurology
Specialities: Haematological disorders | Neurological disorders | Stroke
Summary
This RCT (n=294) reports addition of deferoxamine mesylate in patients with intracerebral haemorrhage did not significantly improve primary outcome of good clinical outcome (defined as a modified Rankin Scale score of 0–2 at day 90).
UKMi comment
At day 90, 34% of participants in the deferoxamine mesylate group vs 33% of patients in the placebo group, had modified Rankin Scale scores of 0–2 (adjusted absolute risk difference 0.6%).
Related links: Comment